PeptiDream saw the highest growth of 1.66% in patent filings in April and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.66% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of PeptiDream’s patent filings and grants. Buy the databook here.
PeptiDream has been focused on protecting inventions in European Patent Office(EPO) with three publications in Q2 2024
The European Patent Office(EPO) Patent Office dominates the patent filings with nearly 22% of filings. The Israel(IL), European Patent Office(EPO), World Intellectual Property Organization(WIPO), and Australia(AU) patent Office are among the top ten patent offices where PeptiDream is filings its patents. Among the top granted patent authorities, PeptiDream has 100% of its grants in United States(US).
Immatics and Harpreet Singh could be the strongest competitors for PeptiDream
Patents related to rare diseases and climate change lead PeptiDream's portfolio
PeptiDream has the highest number of patents in rare diseases followed by, climate change. For rare diseases, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Manufacturing/industrial related patents lead PeptiDream portfolio
PeptiDream has highest number of patents in manufacturing/industrial.
For comprehensive analysis of PeptiDream's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.